Chemotherapy induced nausea and vomiting (2025)

Introduction

Chemotherapy induced nausea and vomiting (CINV) is a common and extremely unpleasant side effect for children receiving antineoplastic therapy. CINV can lead to complications of treatment and cause significant emotional and physical distress, disruptions to activities of daily living and influence the quality of life of the patient. The goal of antiemetic therapy is to prevent vomiting and minimise nausea before, during and after the administration of chemotherapy. The severity of nausea and vomiting can, to some degree, be predicted by the chemotherapeutic agents being delivered but there is a degree of variation between patients. Antiemetic treatments should be initiated prior to the first dose of chemotherapy for best control of nausea and vomiting, as it can often become difficult to control nausea once the child is vomiting. Non-pharmacological measures are also an important consideration and should be implemented in conjunction with pharmacological regimens to allow for the effective management of CINV.

Aim

The aim of this guideline is to provide an overview of the prevention and management of chemotherapy induced nausea and vomiting in the paediatric oncology patient.

Definition of terms

AcuteCINV- CINV occurring within 24 hours of chemotherapy administration; peak intensity often occurs 5 to 6 hours after administration
ALL- acute lymphoblastic leukemia
AML- acute myeloid leukemia
AUC- area under the curve (pharmacokinetics)
Antineoplastic (anticancer)- therapy used to control or kill cancer cells; cytotoxic, hormonal, immunomodulatory, antiviral, biological and molecular targeted therapies may be used
AnticipatoryCINV- CINV occurring within the 24 hour period prior to chemotherapy administration; often provoked by the environment or “thought” of chemotherapy (as example the sight of chemotherapy or when CVAD being accessed)
BARFscale- Baxter Animated Retching Faces scale (pictorial nausea scale)
Breakthrough CINV- CINV occurring despite the use of preventative/prophylactic treatment; a failure to attain the goal of nil nausea and vomiting and a reasonable oral intake; often requires the use of other antiemetics; can be acute or delayed
BSA- body surface area
Chemotherapy- any chemical agent used to treat or control disease; most often used to describe treatment of malignant and other diseases with cytotoxic medicines
CINV- chemotherapy induced nausea and vomiting; may be referred to as antineoplastic induced nausea and vomiting (AINV)
CTZ- chemoreceptor trigger zone
DelayedCINV- CINV occurring 1-5 days after chemotherapy completion with a peak intensity 2-3 days post treatment completion; commonly associated with anthracyclines or platinum agents such as cisplatin or carboplatin
Emesis- the action or process of vomiting
Emetogenicity- likelihood of chemotherapy agent inducing nausea, vomiting or retching
Haematopoieticstem cell transplant (HSCT)- transplantation of the blood forming components/cells of the body
HEC- highly emetogenic chemotherapy (or high emetogenic potential chemotherapy); greater than 90% frequency of emesis in the absence of effective prophylaxis
LEC- low emetogenic chemotherapy (or low emetogenic potential chemotherapy); 10 to less than 30% frequency of emesis in the absence of effective prophylaxis
MEC- moderate emetogenic chemotherapy (or moderate emetogenic potential chemotherapy); 30 to 90% frequency of emesis in the absence of effective prophylaxis
MinEC- minimal emetogenic chemotherapy (or minimal emetogenic potential chemotherapy); less than 10% frequency of emesis in the absence of effective prophylaxis
Nausea- an unpleasant feeling in the throat or stomach that may or may not result in vomiting
NG- nasogastric
Prophylaxis- prevention of
Vomiting- ejecting part or all of the contents of the stomach through the mouth; emesis
VAS- visual analogue scale

Assessment

All patients receiving chemotherapy for childhood cancer or as preconditioning for a haematopoietic stem cell transplant (HSCT) require ongoing assessment of the incidence and severity of nausea and vomiting.

It is the responsibility of nursing staff to regularly assess patients for signs and symptoms of CINV and decide on subsequent methods of management in consultation with the medical team and pharmacy.

The following assessment tools can assist in determining the incidence and severity of CINV. Results of the assessment tools should be clearly documented once per shift (more frequently if indicated) in the Electronic Medical Record (EMR). The CINV score (0 to 10) and type of scale (BARF or VAS) utilized should be recorded under the Nausea Scale assessment in the Observation flowsheet.

Baxterretching faces (BARF) nausea scale

Visual Analogue Scale (VAS)

* Baxter Retching Faces Nausea Scale & Visual Analogue Scale- Baxter et al. (2011)

Each of the scales establishes a score from 0 to 10

A score of0indicatesno nausea
A score of10indicatesworst possible nausea
The assessment tools should be utilised by health professionals to provide an overview of the child’s condition which will allow for an appropriate plan of care based on these findings.

Otherindications of children experiencing CINV may include

Food refusal
Decreased fluid intake
Decreased urine output
Retching
Less interaction with others
Sweating

Managementand principles of prevention and treatment of chemotherapy induced nausea andvomiting

Emetic potential of chemotherapy agents

Chemotherapy agents have different emetic potentials that are classified based on their risk of inducing nausea and vomiting.

MinimalEmetogenic Potential (Minimal Emetogenic Chemotherapy or MinEC)

Less than 10% frequency of emesis in the absence of effective prophylaxis

Low Emetogenic Potential(Low Emetogenic Chemotherapy or LEC)

10 to less than 30% frequency of emesis in the absence of effective prophylaxis

ModerateEmetogenic Potential (Moderate Emetogenic Chemotherapy or MEC)

30 to 90% frequency of emesis in the absence of effective prophylaxis

HighlyEmetogenic Potential (Highly Emetogenic Chemotherapy or HEC)

Greater than 90% frequency of emesis in the absence of effective prophylaxis

Often, combinations of moderately emetogenic agents can yield a course with high emetic potential; for example, both ifosfamide and doxorubicin have moderate emetic potential yet when delivered together have high emetic potential. Other combinations of chemotherapy can have low emetic potential but with extra antiemetic cover required at certain times; for example, ALL induction is generally minimal to low emetic potential but antiemetics are usually required around daunorubicin doses or on days when general anaesthetic has been given. The following provides an outline of the emetic potential of common chemotherapy agents and regimens;

Guide to the emeticpotential of individual chemotherapy agents

Guide to theemetic potential of combination chemotherapy regimens

Antiemetic treatments should be decided based on the emetic potential of the prescribed course of chemotherapy, although there may be some instances where a specific child requires deviations from the guidelines.

Deviations from the guidelines should be discussed with the child’s Oncology Fellow/Consultant and Oncology Pharmacy.
Once an effective antiemetic regimen has been determined for an individual child, this regimen should be used for future courses of chemotherapy as appropriate.
Ensure details of a patient’s personalised antiemetic plan are documented by the Oncology Fellow/Consultant in the Antiemetic Plan tool located in the Oncology Activity in the EMR.

Pharmacological prevention and management of CINV

The goal of antiemetic therapy is to prevent vomiting and minimise nausea both during and after the administration of chemotherapy. For CINV prophylaxis to be effective;

Antiemetics should be prescribed and released to the Medication Administration Record (MAR) from the Treatment Plan under the Oncology Activity on EMR
Antiemetics appropriate for the emetogenic class of the chemotherapy agent or regimen, patient’s age and diagnosis should be
- administered regularly, regardless of nausea or vomiting status (this is to ensure the prevention of breakthrough and delayed CINV)
  - continued throughout the period of administration of chemotherapy and for at least 24 hours following completion of chemotherapy
Ensure antiemetics are ceased 24 to 48 hours following the completion of chemotherapy. Note: agents that cause delayed CINV may require antiemetics for up to 5 days following completion of chemotherapy. If antiemetics are required for longer, please discuss with the oncology fellow/consultant to exclude other causes of nausea and vomiting.

Antiemeticmedications

The first dose of antiemetics should be given prior to commencing chemotherapy as per the following;
- Oral – 30 to 60 minutes prior to first dose of chemotherapy (optimal time is 60 minutes prior)
- Intravenous – immediately before or up to 30 minutes prior to first dose of chemotherapy (optimal time is 30 minutes prior)

Table one: Antiemetic medications

Medication

Dose

Considerations

Ondansetron

5HTз (serotonin) receptor antagonist

Oral/IV 0.15 mg/kg (maximum 8 mg) every 8 hours

Can be given every 6 hours (Paediatric Pharmacopoeia, 13th edition 2013*) with highly emetogenic chemotherapy.

*RCH staff, please note: hardcopy available at the RCH library.

IV administration; Refer to Paediatric Injectable Guidelines

Efficacy is enhanced with Dexamethasone administration

Use in caution with patients with prolonged QT intervals: discuss the use of Ondansetron with fellow or consultant prior to prescribing. Consider concurrent administration of other medications that may prolong the QT interval, for example tyrosine kinase inhibitors (TKI) inhibitors such as Imatinib and Sorafenib

Do not administer other 5HT₃ antagonists concurrently with Ondansetron

First dose can be administered 12 hours after Granisetron (ensure Granisetron is ceased)

First dose can be administered 48 hours after Palonosetron (ensure Palonosetron is ceased)

Palonosetron

5HTз (serotonin) receptor antagonist

Administer as a single dose 30 to 60 minutes prior to the start of chemotherapy

One month to < 17 years: IV 20 mcg/kg (maximum 250 mcg)

17 years and over: IV 250 mcg

IV administration; Refer to Paediatric Injectable Guidelines

Approved for use with

-highly emetogenic chemotherapy (HEC) where Dexamethasone and/or Fosaprepitant/Aprepitant is contraindicated

-moderately emetogenic chemotherapy (MEC) where Dexamethasone is contraindicated

-patients with prolonged QT intervals or those receiving concurrent administration of other medications that may prolong the QT interval, for example tyrosine kinase inhibitors (TKI) inhibitors such as Imatinib and Sorafenib

Do not administer other 5HT₃ antagonists concurrently with Palonosetron

Patients may receive a second dose of Palonosetron at hour 48 of multiday chemotherapy regimens if clinically indicated, discuss with fellow or consultant

Requires DUC approval (Refer to RCH Restricted Drug List)

Dexamethasone

Corticosteroid

Pre chemotherapy loading dose (used for HEC only)

BSA < 0.6 m² : IV 4 mg

BSA 0.6 m² to < 1.5 m² : IV 8 mg

BSA ≥ 1.5 m ² : IV 12 mg

Ongoing dose (start 12 hours after loading dose)

BSA < 0.6 m² : Oral/IV 2 mg every 12 hours

BSA 0.6 m² to < 1.5 m² : Oral/IV 4 mg every 12 hours

BSA ≥ 1.5 m ² : Oral/IV 6 mg every 12 hours

Maximum of 12 doses per course of chemotherapy

If given concurrently with Fosaprepitant or Aprepitant, reduce Dexamethasone dose by half (Fosaprepitant/Aprepitant doubles the Area Under the Curve – AUC of dexamethasone, which is a measure of exposure to dexamethasone)

IV administration; Refer to Paediatric Injectable Guidelines

Not for use in children having chemotherapy for AML without direct fellow or consultant approval – may contribute to immunosuppression

Not for use in patients where corticosteroids are part of their chemotherapy regimen (B & T Cell ALL, NHL)

Not for use in children having chemotherapy for CNS tumours without direct fellow or consultant approval - may impair CNS penetration of chemotherapy

Not for use in patients receiving CAR T cell therapy without direct fellow or consultant approval – may impair CAR T cell activity

Fosaprepitant

Neurokinin-1 (NK-1) receptor antagonist

≥ 6 months (and ≥ 6 kgs) to < 2 years: IV 5 mg/kg as a single dose 30 to 60 minutes before chemotherapy on day 1

2 years to < 12 years: IV 4 mg/kg (maximum 150 mg) as a single dose 30 to 60 minutes before chemotherapy on day 1

12 years and over: adult dosing, 150 mg as a single dose 30 to 60 minutes before chemotherapy on day 1

If Fosaprepitant given concurrently with Dexamethasone, reduce the dose of Dexamethasone by half (Fosaprepitant/Aprepitant doubles the Area Under the Curve – AUC of dexamethasone, which is a measure of exposure to dexamethasone)

IV administration; Refer to Paediatric Injectable Guidelines

Potent antiemetic reserved for highly emetogenic chemotherapy regimens or where breakthrough vomiting has occurred in past courses

Not for use in patients where corticosteroids are part of their chemotherapy treatment (B & T Cell ALL, NHL) without direct fellow or consultant approval

Use with caution in regimens that contain Ifosfamide due to increased risk of neurotoxicity

Patients may receive a second dose of Fosaprepitant at hour 72 of multiday chemotherapy regimens if clinically indicated, discuss with fellow or consultant

Requires DUC approval (Refer to RCH Restricted Drug List)

Aprepitant

Neurokinin-1 (NK-1) receptor antagonist

≥ 6 months (AND ≥ 6 kg) to < 12 years:

Day 1: 1 hour prior to chemotherapy: 3 mg/kg (maximum 125 mg)

Day 2: 2 mg/kg/dose (maximum 80 mg)

Day 3: 2 mg/kg/dose (maximum 80 mg)

≥ 12 years (AND ≥ 30 kg):

Day 1: 1 hour prior to chemotherapy: 165 mg once within 72 hours

If Aprepitant given concurrently with Dexamethasone, reduce the dose of Dexamethasone by half (Fosaprepitant/Aprepitant doubles the Area Under the Curve – AUC of dexamethasone, which is a measure of exposure to dexamethasone)

Oral administration.

Potent antiemetic reserved for highly emetogenic chemotherapy regimens or where breakthrough vomiting has occurred in past courses

Not for use in patients where corticosteroids are part of their chemotherapy treatment (B & T Cell ALL, NHL) without direct fellow or consultant approval

Use with caution in regimens that contain Ifosfamide due to increased risk of neurotoxicity

Course may be extended in some cases if required- discuss with fellow or consultant

Available through Special Access Schemeand DUC approval (Refer to RCH Restricted Drug List)

Olanzapine

Dopamine receptor antagonist

≥ 3 years to < 17 years: Oral 0.1 mg/kg/dose (maximum 10 mg) once daily, round dose to nearest 1.25 mg

17 years and over: Oral 5 to 10 mg

once daily

Daily dose can be divided into twice daily dosing if required.

Antipsychotic with antiemetic action, useful for breakthroughvomiting

Monitor for dizziness, excess sedation and extrapyramidalsymptoms

Concomitant use of CNS depressants (e.g. opioids,benzodiazepines, etc.) increases the risk of respiratory depression andsedation

Do not use concurrently with Metoclopramide or Levomepromazine

May lower the seizure threshold, use cautiously in patients withseizure history

No information for use in children younger than 3 years

Levomepromazine

Dopamine receptor antagonist

≥ 1 year to < 12 years: Oral 0.25 mg/kg/day in 2 to 3 divided doses (maximum 40 mg/day)

≥ 12 years to < 17 years: Oral 3 mg once or twice daily (dose may be increased as necessary and as tolerated to a maximum of 25 mg once or twice daily)

IV 0.05 mg/kg every 12 hours (maximum 25 mg daily), reduce dose by 50% if patient drowsy; if not sedated and still nauseous increase dose by 50%

IV administration; Refer to Paediatric Injectable Guidelines

Use in caution with patients with prolonged QT intervals: discuss the use of Levomepromazine with fellow or consultant prior to prescribing. Consider concurrent administration of other medications that may prolong the QT interval, for example tyrosine kinase inhibitors (TKI) inhibitors such as Imatinib and Sorafenib.

Monitor for excess sedation and extrapyramidal symptoms

Concomitant use of CNS depressants (e.g., opioids, benzodiazepines etc.) increases the risk of respiratory depression and sedation

Do not use concurrently with Metoclopramide, Cyclizine or Olanzapine

May lower the seizure threshold, use cautiously in patients with seizure history

Not recommended for use in children < 1 year due to increased risk of adverse effects

Available through Special Access Scheme (Refer to RCH Restricted Drug List)

Metoclopramide

Dopamine receptor antagonist

Oral/IV 0.15 mg/kg (maximum 10 mg) every 8 hours

Total daily dose should not normally exceed 0.5 mg/kg

IV administration; Refer to Paediatric Injectable Guidelines

Discuss the use of Metoclopramide with fellow or consultant prior to prescribing

Monitor for extrapyramidal symptoms; acute dystonic reactions including oculogyric crises are rare, caution is advised for first exposure to Metoclopramide

If acute dystonic reaction occurs, administer Benzatropine

Do not use concurrently with Olanzapine or Levomepromazine

May lower the seizure threshold, use cautiously in patients with seizure history

Not recommended for use in children < 1 year

Cyclizine

Antihistamine

≥ 1 month to 18 years: oral/IV 0.5 to 1 mg/kg every 8 hours

<12 years: maximum 25 mg per dose

≥12 years: maximum 50 mg per dose

IV administration; Refer to Paediatric Injectable Guidelines

Rapid IV administration can cause drowsiness and dizziness, recommend administering over 30 minutes

Not a powerful antiemetic but may be used if vomiting persists despite recommended regimens

May antagonize the prokinetic effect of Metoclopramide – caution when used in combination

Not recommended for use in children < 1 year due to increased risk of adverse effects

Lorazepam

Benzodiazepine

Oral 0.04 to 0.08 mg/kg/dose (maximum 2 mg per dose)

Administer once at bedtime the night before chemotherapy and once the next day prior to administration of chemotherapy.

Little efficacy as antiemetic alone; not to be administered without additional antiemetics

Useful for anticipatory nausea and vomiting

Concomitant use of CNS depressants (e.g., opioids, benzodiazepines etc.) increases the risk of respiratory depression and sedation.

AntiemeticGuideline

To ensure effective control of CINV, regular antiemetic therapy should be prescribed and administered according to the emetic potential of the chemotherapy agent or regimen. Recommended medications to be used as antiemetic therapy are outlined in the table below.

Antiemetic steroids should notbe used in patients with brain tumours, AML, CAR T cell therapy or patientswith corticosteroids as part of their chemotherapy regimen.

Halve dose of Dexamethasone ifusing Fosaprepitant or Aprepitant.

Table two: Antiemetic guideline

Age

Minimal Emetogenicity

(MinEC)

Low Emetogenicity

(LEC)

Moderate Emetogenicity

(MEC)

High Emetogenicity

(HEC)

Less than 6 months

Regular

Not required

Ondansetron

Dexamethasone

If Dexamethasone is contraindicated recommend:

Change Ondansetron to Palonosetron

Ondansetron

Dexamethasone

Cyclizine

If Dexamethasone is contraindicated recommend:

Change Ondansetron to Palonosetron

For relief of breakthrough nausea and vomiting

Step 1:

Escalate to LEC recommendations

Step 1:

Optimise frequency of prescribed antiemetics

Step 2:

Escalate to MEC recommendations

Step 1:

Optimise frequency of prescribed antiemetics

Step 2:

Escalate to HEC recommendations

Step 1:

Optimise frequency of prescribed antiemetics

Step 2:

Change Ondansetron to Palonosetron

6 months and over

Regular

Not required

Ondansetron

Dexamethasone

If Dexamethasone is contraindicated recommend:

Change Ondansetron to Palonosetron

Ondansetron

Dexamethasone

Fosaprepitant^a,b

If Dexamethasone and/or Fosaprepitant is contraindicated recommend:

Change Ondansetron to Palonosetron

Add Cyclizine

For breakthrough or refractory nausea and vomiting

Step 1:

Escalate to LEC recommendations

Step 1:

Optimise frequency of prescribed antiemetics

Step 2:

Escalate to MEC recommendations

Step 1:

Optimise frequency of prescribed antiemetics

Step 2:

Escalate to HEC recommendations

Step 1:

Optimise frequency of prescribed antiemetics

Step 2:

Change Ondansetron to Palonosetron

Add Cyclizine

Step 3:

Consider adding Metoclopramide, Olanzapine or Levomepromazine

Note: these medications interact, discuss with Oncology Consultant/ Fellow or Pharmacy before prescribing

^a Aprepitant may be used instead of Fosaprepitant

^b Omit Fosaprepitant/Aprepitant if known to interact with chemotherapy agent (monitor for signs of encephalopathy when used with Ifosfamide; anecdotal evidence in adults)

Adapted from the Royal Children’s Hospital, Melbourne (2014) & the National Child Cancer Network, New Zealand (2019)

BreakthroughCINV

Breakthrough nausea and vomiting should be treated promptly. It is advised to have further antiemetics charted on the Treatment Plan under the Oncology Activity on EMR to enable nurses to initiate breakthrough medication as required.

Before prescribing further antiemetics, staff should review the Treatment Plan and contact the Oncology team to release any prescribed antiemetics to the MAR. The suggested order of escalation for breakthrough nausea and vomiting is outlined in the above table. This should be adjusted for individual situations.

Consideration should be given to the contribution of anticipatory nausea and vomiting which is likely to respond better to benzodiazepines and non-pharmacologic management.

Delayed CINV

This is defined as CINV occurring 1-5 days after chemotherapy and is most associated with anthracyclines or platinum agents such as Cisplatin or Carboplatin. Regular antiemetics should be continued for at least 48 hours after completion of Cisplatin and in any other course of chemotherapy where delayed CINV has occurred in the past. Note: agents that cause delayed CINV may require antiemetics for up to 5 days following completion of chemotherapy.

Consideration may be given to a second dose of Fosaprepitant or a second dose of Palonosetron if this is appropriate. Ongoing Dexamethasone and Ondansetron may be sufficient.

Furtherconsiderations

Anticipatory CINV, is common in adolescents and rarely responds to standard antiemetic regimes. Benzodiazepines can be useful in this patient population but do not have direct antiemetic effects. The best treatment for anticipatory CINV is prevention- if patients do not associate chemotherapy with nausea or vomiting, anticipatory CINV may not develop
Dexamethasone should be charted regular (not PRN) if included in antiemetic regimes as the efficacy is enhanced with prophylactic administration
Delayed CINV is common after chemotherapy courses containing Cisplatin. Antiemetics should be continued regularly for at least 48 hours after completing chemotherapy
Ondansetron is as effective as Granisetron and is the 5HTз (serotonin) antagonist of choice for CINV. If Granisetron has been administered pre/post operatively, change antiemetic coverage to Ondansetron if child commencing chemotherapy (may commence administration of Ondansetron 12 hours post Granisetron; use in caution in patients with prolonged QT intervals or on multiple QT prolongating drugs, discuss with fellow or consultant prior to prescribing). Ensure Granisetron is ceased.

Non-pharmacological management of CINV

Despite the advances in pharmacological management, standard pharmacological regimes may not fully alleviate symptoms of CINV in paediatric oncology patients. Non-pharmacological interventions are an important consideration of antiemetic therapy. Non-pharmacological measures should be implemented in conjunction with pharmacological regimes to allow for the effective management of CINV. The use of non-pharmacological measures may not be appropriate for each patient, interventions should be implemented according to the individual patient's needs and circumstances.

Music therapy andrelaxation

Music therapy and relaxation are beneficial interventions in managing CINV with minimal negative side effects. Music therapy may include a) live and active music engagement, and b) individual (recorded) music listening for refocusing and/or relaxation. These interventions are suitable for all ages, are cost effective and can be implemented in the inpatient, outpatient and home environments. The music therapist is available to assess and advise on the most suitable plan for each patient.

Music listening/relaxation during chemotherapy:

Where possible suggest to families to bring familiar music and music playing device for the first period of chemotherapy
Involve a music therapist to assess the capability of children receiving chemotherapy to use music independently
Encourage patients to listen to recorded music that is familiar and that they find comforting and relaxing during periods of chemotherapy (familiar music is the best option)
For patients and families needing guidance the music therapist can make recommendations about styles of music that are effective in promoting relaxation for different age groups
Commence music listening prior to chemotherapy administration or during experiences of anticipatory nausea and vomiting
Contact Music Therapy, Educational Play Therapy or Comfort First Clinicians to assess if patient may benefit from focused breathing exercises to assist relaxation
Encourage periods in a quiet environment
Cluster medical and nursing care to allow for periods of rest

For children aged under 7 years, active music engagement may be more effective than passive music listening. The Music Therapist can advise/plan for this. See also section on Cognitive Distraction.

Guided imagery

Encouraging patients to focus on thoughts and images they find pleasing and relaxing will divert attention from nausea and vomiting to desirable thoughts and images.

Encourage patients to visualise images related to the external environment (nature, landscape images) prior to and during chemotherapy administration
Place appealing images/paintings in patients' rooms during chemotherapyadministration
Encourage patients to reside in areas where they can enjoy the outside view (e.g. by windows) during periods of nausea, vomiting and anxiety
Implement music listening in combination with guided imagery for optimal management of nausea and vomiting

Cognitivedistraction

Cognitive distraction acts to counteract CINV by drawing a patient's attention away from feelings of nausea and vomiting and focusing attention on more pleasant activities. Patients should be encouraged to participate in

Computer games
Movies/Television
Arts and crafts
Developmental / Group play sessions
Active Music Engagement
Education sessions (kinder and school)
Socialisation with family, friends and other patients
Discussions about life outside of the hospital setting (pets, siblings, school, hobbies)
Organising visits from volunteer services and ward grandparents available at the RCH

The Educational Play Therapy, Art Therapy and Music Therapy teams can assist in providing activities that promote cognitive refocussing to effectively manage CINV.

Massage

Educating families to perform massage during periods of chemotherapy has a positive impact on reducing levels of stress, anxiety, nausea and vomiting.
It is not recommended touse massage for the paediatric oncology patient with a low platelet count(platelets ≤ 20-30 x 10e9/L)

Caution should be taken in patients receiving radiation. Avoid massaging areas that have received treatment to reduce irritation of irradiated skin and/or skin breakdown
Caution should be taken in patients with solid tumours. Avoid massaging directly over areas where tumour is present to reduce associated pain and anxiety
The level of pressure applied to the patient should be adjusted in those at risk of peripheral neuropathy
Care should be taken to minimise massage movements that create a rocking motion in patients with nausea and vomiting
Use non scented oils to reduce nausea associated with oil scents
Care should be taken in patients with an accessed port (central venous access device) to avoid trauma

Acupressure

The acupressure technique involves the pressure applied to and then released from acupoints. Acupressure may be performed manually or with wrist pressure bands (also used for motion/travel sickness).

It isnot recommended to use acupressure for the paediatric oncology patient with alow platelet count (platelets ≤ 20-30 x 10e9/L)

Acupressure wrist bands may be applied to children prior to and during chemotherapy administration as tolerated

Manualacupressure

Perform daily during chemotherapy administration in the absence of acupressure wrist bands
Pressure should be applied to acupoints for 1 to 3 minutes and then released
Acupressure should commence prior to administration of chemotherapy and continue for the duration of the chemotherapy cycle
Health professionals should familiarise themselves with the P6 acupressure technique. Adult studies have suggested pressure to the P6 acupoint may assist in the control of nausea and vomiting. The P6 acupoint is located on the inner forearm, located 3 fingerbreadths below the wrist, between the two tendons.
Encourage patients and families to familiarise themselves with the P6 acupressure point technique so they can independently perform this technique during treatment periods

Dietaryconsiderations

The following suggestions may be useful to help manage nausea and vomiting;

Offer bland, dry foods such as toast and dry biscuits
Offer smaller serves of food more frequently
Offer sips of fluid throughout the day, sucking on ice cubes, fizzy drinks such as soda water or dry ginger ale and jellies can assist with an upset stomach
Offer cold foods that have little smell
Eat meals in a well ventilated room to clear the smell of foods away
Encourage oral intake during times when the child feels less nauseated
Discuss with your doctor/medical team about optimising anti-emetics

Enteralnutrition (Nasogastric/PEG feeds)

Consider reducing the rates of NG/PEG feeds during highly emetogenic chemotherapy
If a child is vomiting during NG/PEG feeds, consider pausing the feeds for a short period (e.g. 1 hour) and restarting again at the last tolerated rate. If a child is on overnight NG/PEG feeds consider running total volume, prescribed by the dietitian, over 24 hours
A dietitian can help to alter a child’s feeding regime if needed. Please refer to the dietitian for advice.

Otherconsiderations

A multidisciplinary approach to managing CINV will assist in providing appropriate supportive care and effective antiemetic regimes to the paediatric oncology patient
Current literature supports the use of ginger supplementation to manage general nausea and vomiting, however ginger is not recommended for use in the paediatric oncology population due to unknown effects on coagulation
Poorly controlled CINV can result in dehydration, electrolyte imbalance, anorexia and fatigue
Antiemetic therapies should be routinely administered during chemotherapy administration known to induce nausea and vomiting, not just PRN when patients develop symptoms of nausea
If a patient is being discharged with antiemetic medications, the patient and/or caregivers should be given instructions on the management of antiemetic regimes at home prior to discharge
The use of various forms of non-pharmacological and complementary therapies has also found to reduce nausea, vomiting and fatigue intensity, however should be discussed with the medical team prior to use
Rinse the mouth thoroughly after vomiting with water (stomach acid left in contact with the teeth and the mouth lining will cause tooth decay and irritate the mouth)

Companiondocuments

Informationfor parents

Informationfor Health Professionals

Children’s Oncology Group (2022), Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients. COG Supportive Care Endorsed Guidelines, Children’sOncology Group (COG), Version date: July 15, 2022
eviQ Clinical Resource; Prevention of antineoplastic induced nausea and vomiting
Medicines information
National Child Cancer Network New Zealand (2019), Clinical Guideline: Nausea and vomiting - chemotherapy and radiotherapy induced: prevention and treatment, Version date: 12 August, 2019

Evidence table

The evidence table for this guideline can be found here.

Please remember to read the disclaimer.

The development of this nursing guideline was coordinated by Lisa Barrow,CNE, Kookaburra, and approved by the Nursing Clinical Effectiveness Committee. Updated May 2023.